PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022 - San Diego, California Talk Radio Station - 760 KFMB AM - 760kfmb

PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02029810/PharmaPoint-Osteoporosis---Global-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022

Summary

Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

Highlights

Key Questions Answered

- Bisphosphonates and selective estrogen receptor modulators (SERMs) dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?
- Six major brands are due to lose patent protection before 2015. How will these patent expiries as well as new product launches impact the osteoporosis therapeutics market?
- The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022? Which will have the highest peak sales at the highest CAGR, and why?
- The osteoporosis patient population in the targeted geographies will increase marginally from 2012-2012 with the increase of the overall disease population. How will epidemiological changes impact the growth of the future market?

Scope

- Overview of osteoporosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized osteoporosis therapeutics market revenue, annual cost of therapy and treatment usage pattern data 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the osteoporosis therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including anti-sclerostin antibodies, cathepsin K inhibitors, SERMs with conjugated estrogens, and human parathyroid hormone related protein.
- Analysis of the current and future market competition in the global osteoporosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global osteoporosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global osteoporosis therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global osteoporosis therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20

3.1 Etiology and Pathophysiology 20
3.1.1 Etiology 20
3.1.2 Pathophysiology 23
3.1.3 Risk Factors 24
3.1.4 Quality of Life 24
3.2 Symptoms 25
4 Epidemiology 26
4.1 Risk Factors and Comorbidities 26
4.1.1 Advanced age and female sex are the leading risk factors for osteoporosis 26
4.1.2 Low body mass index (BMI) and physical inactivity can lead to significant bone loss 26
4.1.3 Previous osteoporotic fracture increases risk of subsequent fracture 27
4.1.4 Certain diseases and medications increase the risk of osteoporosis 28
4.1.5 Malnutrition and a nutrient-poor diet decrease BMD 28
4.1.6 Smoking is an independent risk factor for osteoporosis 29
4.1.7 Limited daily alcohol consumption may have a protective effect 29
4.2 Global and Historical Trends 30
4.2.1 United States 30
4.2.2 Five EU Markets 31
4.2.3 Asia 32
4.3 Forecast Methodology 34
4.3.1 Sources Used 35
4.3.2 Forecast Assumptions and Methods 38
4.3.3 Sources Not Used 41
4.4 Epidemiology Forecast (2012-2022) 42
4.4.1 Total Prevalent Cases of Osteoporosis 42
4.4.2 Age-Specific Prevalent Cases of Osteoporosis 43
4.4.3 Sex-Specific Total Prevalent Cases of Osteoporosis 44
4.5 Discussion 46

4.5.1 The Strength of GlobalData's Epidemiologic Projections 48
5 Disease Management 49
5.1 Treatment Overview 49
5.1.1 Diagnosis and Referral 49
5.1.2 Treatment Guidelines 50
5.1.3 Disease Management 51
5.2 United States 54
5.2.1 Diagnosis 54
5.2.2 Clinical Practice 55
5.3 United Kingdom 56
5.3.1 Diagnosis 56
5.3.2 Clinical Practice 57
5.4 France 58
5.4.1 Diagnosis 58
5.4.2 Clinical Practice 58
5.5 Germany 59
5.5.1 Diagnosis 59
5.5.2 Clinical Practice 60
5.6 Spain 61
5.6.1 Diagnosis 61

5.6.2 Clinical Practice 61
5.7 Italy 62
5.7.1 Diagnosis 62
5.7.2 Clinical Practice 63
5.8 Japan 63
5.8.1 Diagnosis 63
5.8.2 Clinical Practice 63
5.9 China 64
5.9.1 Diagnosis 64
5.9.2 Clinical Practice 65
5.10 India 65
5.10.1 Diagnosis 65
5.10.2 Clinical Practice 66
6 Competitive Assessment 67
6.1 Overview 67
6.2 Strategic Competitor Assessment 67
6.3 Product Profiles - Major Brands 71
6.3.1 Actonel (risedronate sodium) 71
6.3.2 Evista (raloxifene hydrochloride) 75
6.3.3 Reclast (zolendronic acid) 79
6.3.4 Forteo (teriparatide) 83
6.3.5 Prolia (denosumab) 87
6.3.6 Protelos (strontium ranelate) 91
6.3.7 Miacalcin and Fortical (calcitonin-salmon) 94
6.3.8 Viviant/Conbriza (bazedoxifene) 99
6.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 103
6.3.10 Alendronate sodium 106
6.3.11 Ibandronate 109
7 Opportunity and Unmet Need 111
7.1 Overview 111
7.2 Unmet Needs 111
7.2.1 Disease Awareness and Early Diagnosis 111
7.2.2 Patient Compliance 112
7.2.3 Efficacy 113
7.2.4 Safety 113

7.2.5 Treatment Cost 114
7.2.6 Earlier Intervention 114
7.3 Unmet Needs Gap Analysis 115
7.4 Opportunity 1: Dual-Action Therapies 116
7.5 Opportunity 2: Osteoporosis Prevention Therapies 117
7.6 Opportunity 3: Dosing and Administration 118
8 Pipeline Assessment 119
8.1 Overview 119
8.2 Clinical Trial Mapping 120
8.2.1 Clinical Trials by Country 120
8.3 Clinical Trials by Phase and Trial Status 120
8.3.1 Overview of Selected Late-Phase Development Programs 122
8.4 Promising Drugs in Clinical Development 123
8.4.1 Aprela (bazedoxifene and conjugated estrogens) 124
8.4.2 Romosozumab (AMG-785) 131
8.4.3 Odanacatib 137
8.4.4 BA-058 143
8.4.5 PTH(1-31)NH2 148
8.4.6 Ostora (recombinant salmon calcitonin) 153
9 Current and Future Players 158
9.1 Overview 158
9.2 Trends in Corporate Strategy 159
9.3 Company Profiles 160
9.3.1 Amgen 160
9.3.2 Merck 162
9.3.3 Eli Lilly 165
9.3.4 Pfizer 168
9.3.5 Radius Health 170
10 Market Outlook 173

10.1 Global Markets 173
10.1.1 Forecast 173
10.1.2 Drivers and Barriers - Global Issues 175
10.2 United States 177
10.2.1 Forecast 177
10.2.2 Key Events 180
10.2.3 Drivers and Barriers 180
10.3 France 182
10.3.1 Forecast 182
10.3.2 Key Events 185
10.3.3 Drivers and Barriers 185
10.4 Germany 187
10.4.1 Forecast 187
10.4.2 Key Events 190
10.4.3 Drivers and Barriers 190
10.5 Italy 192
10.5.1 Forecast 192
10.5.2 Key Events 195
10.5.3 Drivers and Barriers 195
10.6 Spain 197

10.6.1 Forecast 197
10.6.2 Key Events 200
10.6.3 Drivers and Barriers 201
10.7 United Kingdom 202
10.7.1 Forecast 202
10.7.2 Key Events 205
10.7.3 Drivers and Barriers 205
10.8 Japan 208
10.8.1 Forecast 208
10.8.2 Key Events 211
10.8.3 Drivers and Barriers 211
10.9 India 213
10.9.1 Forecast 213
10.9.2 Key Events 215
10.9.3 Divers and Barriers 216
10.10 China 217
10.10.1 Forecast 217
10.10.2 Key Events 219

10.10.3 Drivers and Barriers 220
11 Appendix 221
11.1 Bibliography 221
11.2 Abbreviations 237
11.3 Methodology 240
11.4 Forecasting Methodology 240
11.4.1 Diagnosed Osteoporosis Patients 240
11.4.2 Percent Drug-Treated Patients 240
11.4.3 Drugs Included in Each Therapeutic Class 241
11.4.4 Launch and Patent Expiry Dates 241
11.4.5 General Pricing Assumptions 242
11.4.6 Individual Drug Assumptions 242
11.4.7 Generic Erosion 246
11.4.8 Pricing of Pipeline Agents 246
11.5 Physicians and Specialists Included in this Study 247
11.5.1 About the Authors 248
11.5.2 Global Head of Healthcare 249
11.6 About GlobalData 250
11.7 Contact Us 250
11.8 Disclaimer 250

List of Tables

Table 1: Etiology of Primary Osteoporosis 20
Table 2: Etiology of Secondary Osteoporosis 22
Table 3: Symptoms of Osteoporosis 25
Table 4: Nine Major Markets, Sources of Osteoporosis Prevalence Data 34
Table 5: Nine Major Markets, Prevalent Cases of Osteoporosis, N (millions), 2012-2022 42
Table 6: Nine Major Markets, Prevalent Cases of Osteoporosis, By Age, N (millions), %, 2012 43
Table 7: Diagnostic Tests for Osteoporosis 49
Table 8: T-Score Ranges for Determination of BMD 50
Table 9: Treatment Guidelines for Osteoporosis 51
Table 10: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 52
Table 11: Leading Treatments for Osteoporosis, 2012 70
Table 12: Product Profile - Actonel 72
Table 13: Actonel SWOT Analysis, 2012 73
Table 14: Global Sales Forecasts ($m) for Actonel, 2012-2022 74
Table 15: Product Profile - Evista 76
Table 16: Evista SWOT Analysis, 2012 77
Table 17: Global Sales Forecasts ($m) for Evista, 2012-2022 78
Table 18: Product Profile - Reclast 80
Table 19: Reclast SWOT Analysis, 2012 81
Table 20: Global Sales Forecasts ($m) for Reclast, 2012-2022 82
Table 21: Product Profile - Forteo 83
Table 22: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 84
Table 23: Forteo SWOT Analysis, 2012 85
Table 24: Global Sales Forecasts ($m) for Forteo, 2012-2022 86
Table 25: Product Profile - Prolia 87
Table 26: Prolia SWOT Analysis, 2012 89

Table 27: Global Sales Forecasts ($m) for Prolia, 2012-2022 90
Table 28: Product Profile - Protelos 91
Table 29: Protelos SWOT Analysis, 2012 92
Table 30: Global Sales Forecasts ($m) for Protelos, 2012-2022 94
Table 31: Product Profile - Miacalcin and Fortical Nasal Spray 95
Table 32: Adverse Events with Miacalcin Nasal Spray 96
Table 33: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 97
Table 34: Global Sales Forecast ($m) for Miacalcin Nasal Spray, 2012-2022 98
Table 35: Global Sales Forecast ($m) for Fortical Nasal Spray, 2012-2022 99
Table 36: Product Profile - Viviant/Conbriza 100
Table 37: Viviant/Conbriza SWOT Analysis, 2012 101
Table 38: Global Sales Forecasts ($m) for Viviant/Conbriza, 2012-2022 102
Table 39: Product Profile - Recalbon/Bonoteo 103
Table 40: Recalbon/Bonoteo SWOT Analysis, 2012 104
Table 41: Global Sales Forecasts ($m) for Recalbon/Bonoteo, 2012-2022 105
Table 42: Global Sales Forecasts ($m) for alendronate, 2012-2022 108
Table 43: Global Sales Forecasts ($m) for ibandronate, 2012-2022 110
Table 44: Overall Unmet Needs - Current Level of Attainment 111
Table 45: Clinical Unmet Needs - Gap Analysis, 2012 115
Table 46: Osteoporosis - Clinical Trials by Phase and Status, 2012 121

Table 47: Osteoporosis - Pipeline, 2012 123
Table 48: Comparison of Therapeutic Classes in Development for Osteoporosis, 2012 123
Table 49: Product Profile - Aprela 125
Table 50: Aprela SWOT Analysis, 2012 129
Table 51: Global Sales Forecasts ($m) for Aprela, 2012-2022 130
Table 52: Product Profile - Romosozumab 131
Table 53: Romosozumab SWOT Analysis, 2012 135
Table 54: Global Sales Forecasts ($m) for Romosozumab, 2012-2022 136
Table 55: Product Profile - Odanacatib 137
Table 56: Odanacatib SWOT Analysis, 2012 141
Table 57: Global Sales Forecasts ($m) for Odanacatib, 2012-2022 142
Table 58: Product Profile - BA-058 143
Table 59: BA-058 SWOT Analysis, 2012 146
Table 60: Global Sales Forecasts ($m) for BA-058, 2012-2022 147
Table 61: Product Profile - PTH(1-31)NH2 148
Table 62: PTH(1-31)NH2 SWOT Analysis, 2012 151
Table 63: Global Sales Forecasts ($m) for PTH(1-31)NH2, 2012-2022 152
Table 64: Product Profile - Ostora 154
Table 65: Ostora SWOT Analysis, 2012 156
Table 66: Global Sales Forecasts ($m) for Ostora, 2012-2022 157
Table 67: Key Companies in the Osteoporosis Market, 2012 158
Table 68: Amgen's Osteoporosis Therapy Portfolio Assessment, 2012 161
Table 69: Amgen SWOT Analysis, 2012 161
Table 70: Merck's Osteoporosis Therapy Portfolio Assessment, 2012 163
Table 71: Merck SWOT Analysis, 2012 164
Table 72: Eli Lilly's Osteoporosis Therapy Portfolio Assessment, 2012 166
Table 73: Eli Lilly SWOT Analysis, 2012 166
Table 74: Pfizer's Osteoporosis Therapy Portfolio Assessment, 2012 168
Table 75: Pfizer SWOT Analysis, 2012 169
Table 76: Radius Health's Osteoporosis Therapy Portfolio Assessment, 2012 171
Table 77: Radius Health SWOT Analysis, 2012 171
Table 78: Global Sales Forecasts ($) for Osteoporosis, 2012-2022 174
Table 79: Osteoporosis Market - Drivers and Barriers, 2012-2022 175
Table 80: US Sales Forecasts ($) for Osteoporosis, 2012-2022 178
Table 81: Key Events Impacting Sales for Osteoporosis in the US, 2012-2022 180
Table 82: Osteoporosis Market - Drivers and Barriers in the United States, 2012-2022 180
Table 83: France Sales Forecasts ($) for Osteoporosis, 2012-2022 183
Table 84: Key Events Impacting Sales for Osteoporosis in France, 2012-2022 185
Table 85: Osteoporosis Market - Drivers and Barriers in France, 2012-2022 185
Table 86: Germany Sales Forecasts ($) for Osteoporosis, 2012-2022 188
Table 87: Key Events Impacting Sales for Osteoporosis in Germany, 2012-2022 190
Table 88: Osteoporosis Market - Drivers and Barriers in Germany, 2012-2022 190

Table 89: Italy Sales Forecasts ($) for Osteoporosis, 2012-2022 193
Table 90: Key Events Impacting Sales for Osteoporosis in Italy, 2012-2022 195
Table 91: Osteoporosis Market - Drivers and Barriers in Italy, 2012-2022 195
Table 92: Spain Sales Forecasts ($) for Osteoporosis, 2012-2022 198
Table 93: Key Events Impacting Sales for Osteoporosis in the Spain, 2012-2022 200
Table 94: Osteoporosis Market - Drivers and Barriers in Spain, 2012-2022 201
Table 95: UK Sales Forecasts ($) for Osteoporosis, 2012-2022 203
Table 96: Key Events Impacting Sales for Osteoporosis in the UK, 2012-2022 205
Table 97: Osteoporosis Market - Drivers and Barriers in the United Kingdom, 2012-2022 205
Table 98: Japan Sales Forecasts ($) for Osteoporosis, 2012-2022 209
Table 99: Key Events Impacting Sales for Osteoporosis in Japan, 2012-2022 211
Table 100: Osteoporosis Market - Drivers and Barriers in Japan, 2012-2022 211
Table 101: India Sales Forecasts ($) for Osteoporosis, 2012-2022 214
Table 102: Key Events Impacting Sales for Osteoporosis in India, 2012-2022 215
Table 103: Osteoporosis Market - Drivers and Barriers in India, 2012-2022 216
Table 104: China Sales Forecasts ($) for Osteoporosis, 2012-2022 218
Table 105: Key Events Impacting Sales for Osteoporosis in the China, 2012-2022 219
Table 106: Osteoporosis Market - Drivers and Barriers in China, 2012-2022 220
Table 107: Key Launch Dates 241
Table 108: Key Patent Expiries 241
Table 109: Number of High-Prescribing Physicians Surveyed 247

1.2 List of Figures
Figure 1: Nine Major Markets, Prevalent Cases of Osteoporosis, By Age, N (millions), 2012 44
Figure 2: Nine Major Markets, Prevalent Cases of Osteoporosis, By Sex, N, 2012 45
Figure 3: Osteoporosis Therapeutics - Ongoing Clinical Trials by Country, 2012 120
Figure 4: Osteoporosis Therapeutics - Late-Phase Development Programs of Leading Pipeline Drugs 122
Figure 5: Company Portfolio Gap Analysis in Osteoporosis, 2012-2022 124
Figure 6: Company Portfolio Gap Analysis in Osteoporosis, 2012-2022 159
Figure 7: Global Sales for Osteoporosis by Region, 2012-2022 175
Figure 8: Sales for Branded Osteoporosis Drugs in the United States by Drug Class, 2012-2022 179
Figure 9: Sales for Branded Osteoporosis Drugs in France by Drug Class, 2012-2022 184
Figure 10: Sales for Branded Osteoporosis Drugs in Germany by Drug Class, 2012-2022 189
Figure 11: Sales for Branded Osteoporosis Drugs in Italy by Drug Class, 2012-2022 194
Figure 12: Sales for Branded Osteoporosis Drugs in Spain by Drug Class, 2012-2022 199
Figure 13: Sales for Branded Osteoporosis in the UK by Drug Class, 2012-2022 204
Figure 14: Sales for Branded Osteoporosis Drugs in Japan by Drug Class, 2012-2022 210
Figure 15: Sales for Branded Osteoporosis Drugs in India by Drug Class, 2012-2022 215
Figure 16: Sales for Branded Osteoporosis Drugs in China by Drug Class, 2012-2022 219

To order this report: PharmaPoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02029810/PharmaPoint-Osteoporosis---Global-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Midwest Television, Inc. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.